Furthermore, levels of VWF, and TM (combined with ICAM-1 and E-selectin level) measured one week after HCT were used as SOS predicting biomarker in patients treated with both tacrolimus and sirolimus as GVHD prophylaxis (65). Here, VWF is linked to graft versus host disease.